Drugs / DTP348
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02216669 | Mar → Jun 2017 | cancer, head and neck neoplasm | Maastricht Radiation Oncology | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTP 348 | “DTP 348 is an oral dual drug with two mechanisms of action:” NCT02216669 ↗ |
| Action | Inhibit | “carbonic anhydrase IX inhibitor” NCT02216669 ↗ |
| Modality | Small molecule | “Toxicity that can be expected from DTP348 is related to the nitro-imidazole compound” NCT02216669 ↗ |
| Route | Oral | “Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks” NCT02216669 ↗ |